SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
112 hedge funds and large institutions have $26M invested in SANGAMO THERAPEUTICS INC in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 30 increasing their positions, 16 reducing their positions, and 16 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 16
81% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 16
12.82% more ownership
Funds ownership: 18.5% → 31.32% (+13%)
7% more funds holding
Funds holding: 105 → 112 (+7)
9% more call options, than puts
Call options by funds: $344K | Put options by funds: $315K
0% less capital invested
Capital invested by funds: $26.2M → $26M (-$127K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$16.1M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$2.1M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$694K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$615K |
| 5 |
Two Sigma Investments
New York
|
+$603K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$1.83M |
| 2 |
Jane Street
New York
|
-$1.16M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$595K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$179K |
| 5 |
GCM
Graham Capital Management
Rowayton,
Connecticut
|
-$135K |
SGMO Hedge Fund Activity: Q1 2026 in Review
112 of the 8,141 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q1 2026, worth a combined $26M — down 0.48% from $26.2M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new SGMO positions and 16 closed out — a net gain of 13 holders — while 30 added to existing stakes and 16 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $16.1M. The largest seller was Renaissance Technologies, cutting an estimated $1.83M.
- 112 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q1 2026, up from 105 in Q4 2025.
- Funds reported $26M of SANGAMO THERAPEUTICS INC stock for Q1 2026, down 0.48% quarter-over-quarter.
- 29 funds opened new SANGAMO THERAPEUTICS INC positions in Q1 2026 and 16 closed out, a net change of +13 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q1 2026 was Armistice Capital, an estimated $16.1M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q1 2026 was Renaissance Technologies, an estimated $1.83M sold.
Based on aggregated 13F filings for Q1 2026.